publication date: Feb. 3, 2017

Cancer groups: Trump travel ban could “retard scientific progress and adversely affect public health”

By Matthew Bin Han Ong

President Donald Trump’s recent executive order that temporarily bars travel from seven Muslim-majority countries to the United States will negatively affect research institutions, public health, and innovation, cancer organizations say.

The order, issued Jan. 27, prohibits citizens from Iraq, Syria, Iran, Libya, Somalia, Sudan, and Yemen from entering the U.S. for the next 90 days. Trump’s move dramatically expands on a December 2015 law—signed by former President Barack Obama—which placed restrictions on certain travelers who had visited these seven countries, in an effort to address “the growing threat from foreign terrorist fighters.”

In a joint statement, six groups expressed “deep concern” about Trump’s executive order, which has “denied U.S. entry to people who bring unique expertise to the practice of medicine and the conduct of cancer and biomedical research.”

The groups are: the American Society of Hematology, the American Association for Cancer Research, the Association of American Cancer Institutes, the American Society for Radiation Oncology, The American Society of Pediatric Hematology/Oncology, and the LUNGevity Foundation.

“We respectfully call on the administration to consider the negative impact of its executive order on our nation’s ability to attract the world’s best scientific and clinical talent to participate … Continue reading Cancer groups: Trump travel ban could “retard scientific progress and adversely affect public health”

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.